Last reviewed · How we verify
NCT05089578
Integrative Treatment Methods in COVID-19
trial testing focus interview in COVID-19 in 12 participants. Completed in 15 October 2021.
15 October 2021
Quick facts
| Lead sponsor | Amasya University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12 |
| Start date | 15 July 2021 |
| Primary completion | 15 October 2021 |
| Estimated completion | 15 October 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- focus interview
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Patient Experience — all drugs for Patient Experience →
- Health Attitude — all drugs for Health Attitude →
Sponsor
Amasya University
Who can join
Eligibility, any sex, with COVID-19 or Patient Experience. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was conducted to examine the use of integrative treatment methods by individuals undergoing Covid-19. In this study, which was designed in the qualitative and phenomenological type, the criterion sampling method was used and 12 people were included in the sample.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Use of Integrative Treatment Methods by Individuals With COVID-19.
Doğan N, Fışkın G. · · 2022 · PMID 35125979 · DOI 10.1016/j.nurpra.2022.01.004
Verify or expand the search:
- PubMed search for NCT05089578
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Amasya University trials
Trials by the same sponsor.
- NCT07512999 — The Effect of Using Nature Sounds and Virtual Reality During the Non-Stress Test · NA · not yet recruiting
- NCT07510555 — The Effect of a Mindfulness-Based Stress Reduction Program Applied to Nulliparous Pregnant Women · NA · not yet recruiting
- NCT07485790 — The Effects of Yoga on Pregnant Women · NA · recruiting
- NCT07360392 — BiFeS vs. iPACK in Postoperative Knee Arthroplasty Analgesia · NA · not yet recruiting
- NCT07343414 — Effect of Anesthesia Technique on Surgical View in Shoulder Arthroscopy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05089578 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amasya University
- Last refreshed: 22 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05089578.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing